J&J Launches Drug Marketing on TrumpRx Website

Johnson & Johnson began marketing four of its medications on the Trump administration's TrumpRx website on Friday, April 25, 2026.

Objective Facts

Johnson & Johnson officially began marketing four of its medications on the Trump administration's TrumpRx website on Friday, April 25, 2026, following a voluntary agreement announced in January to lower costs by providing Medicaid access to affordable prescriptions and marketing its drugs on TrumpRx in exchange for exemption from the president's tariff agenda. The four drugs include metformin, metformin extended relief, Invokana, and Xarelto. The company has also agreed to invest $55 billion in research and production sites in Pennsylvania and North Carolina. The addition of J&J to TrumpRx more than doubled the number of drugs featured on the low-cost site since its launch in February. However, critics note that J&J and all 16 companies that signed Trump deals still raised prices on 872 brand-name drugs in the first two weeks of January 2026, with a median increase of 4%.

Left-Leaning Perspective

House Energy and Commerce Committee Ranking Member Frank Pallone Jr. (D-NJ) issued a statement calling 'TrumpRx is not a serious effort to lower prescription drug prices,' arguing that if Trump was serious, he would work with Democrats on Medicare price negotiation and other broader reforms rather than relying on voluntary agreements. Senate Finance Committee Ranking Member Ron Wyden (D-Ore.) went further, releasing a report in April 2026 declaring 'There is no greater fraud when it comes to lower prescription drug prices than Donald J. Trump,' arguing that after spending the year with Big Pharma CEOs, Trump has produced only 'sweetheart deals that shower goodies on these companies.' Wyden's report 'Trump's Big Pharma Giveaway' details how the drug deals are 'a sham that benefits pharmaceutical corporations' while offering minimal patient savings, noting that 'any potential savings for state Medicaid programs are unknown and likely to be minimal,' and that companies are receiving tariff relief, exemption from other Trump initiatives, and Priority Review Vouchers for faster FDA approval. During a Senate Finance Committee hearing in April 2026, Sen. Elizabeth Warren (D-Mass.) grilled HHS Secretary Robert F. Kennedy Jr., noting that an analysis by the Center for American Progress found the TrumpRx website offered genuinely lower prices on 'exactly one' of the 54 medications listed, and that in exchange for participating, pharmaceutical companies have received exemptions from Trump's 100% tariffs, saying 'Big Pharma makes billions of dollars in tariff relief by listing their drugs on TrumpRx.' Harvard Medical School professor Aaron Kesselheim stated that TrumpRx deals are voluntary with no enforcement measures and 'do not broadly address the policy issues that lead to high prices,' concluding 'I'm not surprised that the end result is something that is not workable for the vast, vast majority of patients.' A Democratic Energy and Commerce Committee report found that for nearly half of the 43 drugs listed on TrumpRx, there is little to no change to pre-existing discounted prices, that at least 15 drugs have cheaper generic versions not disclosed on the platform, and that at least seven medications have pre-existing GoodRx coupons at the same or nearly same price.

Right-Leaning Perspective

At an Oval Office press conference in December 2025, President Trump declared the most-favored nation drug pricing deals 'the greatest victory for patient affordability in the history of American health care, by far,' noting that 'pharmaceutical companies were difficult, but they also love our country.' When announcing the Regeneron deal in April 2026, Trump stated the discounts 'should be front page news,' positioning the J&J launch as part of his broader achievement in drug pricing. The White House framed the 17th MFN agreement as 'a historic effort to strengthen the program for the most vulnerable Americans,' with the agreement 'providing every State Medicaid program in the country access to MFN drug prices, resulting in hundreds of millions in savings.' The White House fact sheet emphasized that 'the President's 17th MFN deal' covers 'the 17 leading pharmaceutical manufacturers, representing 86% of the branded drug market,' and that 'each of these manufacturers has agreed to fundamentally rebalance international drug pricing by providing MFN pricing to American patients.' A Daily Caller analysis by pollster Jim McLaughlin argued that 'the left-wing media and Democratic critics have spent months trying to convince the public that the president's voluntary Most Favored Nation pricing agreements are insufficient or ineffective,' but that 'President Trump has delivered real results on drug pricing, and our new national survey makes clear those results are a political asset Republicans cannot afford to ignore heading into the 2026 midterms.' Trump signaled confidence in the political returns, saying of the Regeneron deal and broader MFN strategy, 'By itself, we should win the midterms,' reflecting the administration's view that drug pricing has become a winning electoral issue for Republicans.

Deep Dive

The specific angle of this story is whether J&J's launch of four drugs on TrumpRx represents genuine drug pricing reform or a corporate benefit arrangement disguised as affordability. The January 2026 voluntary agreement required J&J to lower costs by providing Medicaid access to affordable prescriptions and marketing drugs on TrumpRx in exchange for exemption from the president's tariff agenda. The core tension is that both sides claim partial victory: the administration highlights discounts on specific drugs and J&J's $55 billion manufacturing commitment, while critics point out that J&J and all 16 signatory companies simultaneously raised prices on 872 brand-name drugs in early 2026, negating the headline gains. A fair reading reveals that TrumpRx does deliver real, measurable discounts on certain drugs—particularly GLP-1 weight-loss medications. However, these discounts apply only to cash-paying uninsured patients (approximately 15% of Americans), while insured patients (85%) typically get better prices through their insurance plans or existing coupons. Additionally, the deals lack enforcement mechanisms and durability; these arrangements are limited to a small number of medications and may not be sustained, as none are enshrined in legislation. Democrats' criticism that J&J is receiving hundreds of millions in tariff relief in exchange for modest price cuts on a handful of drugs has merit, especially given the simultaneous price increases on non-deal medications. Conversely, the administration's claim that they have secured commitments from 15 of 17 major drugmakers and created a centralized platform (TrumpRx) is not without achievement, even if the scope of impact is more limited than rhetoric suggests. What remains to watch is whether these voluntary agreements hold, whether companies maintain pricing discipline on non-deal drugs, whether Democrats' preferred Medicare negotiation approach yields better sustained results, and whether the midterm elections validate the political bet that Trump's drug pricing efforts will move voters. The lack of transparency around deal terms continues to prevent rigorous evaluation of whether patients will actually benefit more than corporations.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

J&J Launches Drug Marketing on TrumpRx Website

Johnson & Johnson began marketing four of its medications on the Trump administration's TrumpRx website on Friday, April 25, 2026.

Apr 24, 2026· Updated Apr 26, 2026
What's Going On

Johnson & Johnson officially began marketing four of its medications on the Trump administration's TrumpRx website on Friday, April 25, 2026, following a voluntary agreement announced in January to lower costs by providing Medicaid access to affordable prescriptions and marketing its drugs on TrumpRx in exchange for exemption from the president's tariff agenda. The four drugs include metformin, metformin extended relief, Invokana, and Xarelto. The company has also agreed to invest $55 billion in research and production sites in Pennsylvania and North Carolina. The addition of J&J to TrumpRx more than doubled the number of drugs featured on the low-cost site since its launch in February. However, critics note that J&J and all 16 companies that signed Trump deals still raised prices on 872 brand-name drugs in the first two weeks of January 2026, with a median increase of 4%.

Left says: Democrats argue that TrumpRx is not a serious effort to lower prescription drug prices. Wyden's report shows these agreements are 'sweetheart deals for Big Pharma,' with Wyden calling Trump's approach 'the greatest fraud when it comes to lower prescription drug prices.'
Right says: Trump and his administration frame the J&J deal and broader MFN agreements as 'the greatest victory for patient affordability in the history of American health care.' The White House emphasizes that the 17 MFN deals cover 86% of the branded drug market and ensure 'MFN pricing to American patients.'
✓ Common Ground
Some voices on both the left and right acknowledge that certain specific drugs—particularly obesity medications like GLP-1s—have achieved meaningful discounts on TrumpRx. Both Democrats and Republicans note that obesity drugs Zepbound from Eli Lilly and Novo's Wegovy saw prices cut to between $149 and $350 a month on average for Americans, down from an initial list price of more than $1000 a month.
Several commentators across the political spectrum acknowledge that transparency around the deals remains inadequate. Congressional calls for transparency on the confidential deal terms have gone unanswered by Health and Human Services Secretary Robert F. Kennedy Jr., a concern raised by both Democratic senators and conservative organizations skeptical of the approach.
Analysts across the spectrum recognize that TrumpRx primarily benefits uninsured cash-paying patients rather than the vast majority of Americans with insurance coverage. Health policy experts caution that 'the impact would likely be muted, especially for the 85 percent of Americans who have prescription drug coverage.'
Both left and right acknowledge that voluntary agreements face inherent limitations compared to mandatory pricing controls. Experts note that broader, mandatory MFN pricing 'could face political headwinds,' as 'historically, Republicans have not been in support of efforts to regulate drug prices,' and pharmaceutical companies would push back.
Objective Deep Dive

The specific angle of this story is whether J&J's launch of four drugs on TrumpRx represents genuine drug pricing reform or a corporate benefit arrangement disguised as affordability. The January 2026 voluntary agreement required J&J to lower costs by providing Medicaid access to affordable prescriptions and marketing drugs on TrumpRx in exchange for exemption from the president's tariff agenda. The core tension is that both sides claim partial victory: the administration highlights discounts on specific drugs and J&J's $55 billion manufacturing commitment, while critics point out that J&J and all 16 signatory companies simultaneously raised prices on 872 brand-name drugs in early 2026, negating the headline gains.

A fair reading reveals that TrumpRx does deliver real, measurable discounts on certain drugs—particularly GLP-1 weight-loss medications. However, these discounts apply only to cash-paying uninsured patients (approximately 15% of Americans), while insured patients (85%) typically get better prices through their insurance plans or existing coupons. Additionally, the deals lack enforcement mechanisms and durability; these arrangements are limited to a small number of medications and may not be sustained, as none are enshrined in legislation. Democrats' criticism that J&J is receiving hundreds of millions in tariff relief in exchange for modest price cuts on a handful of drugs has merit, especially given the simultaneous price increases on non-deal medications. Conversely, the administration's claim that they have secured commitments from 15 of 17 major drugmakers and created a centralized platform (TrumpRx) is not without achievement, even if the scope of impact is more limited than rhetoric suggests.

What remains to watch is whether these voluntary agreements hold, whether companies maintain pricing discipline on non-deal drugs, whether Democrats' preferred Medicare negotiation approach yields better sustained results, and whether the midterm elections validate the political bet that Trump's drug pricing efforts will move voters. The lack of transparency around deal terms continues to prevent rigorous evaluation of whether patients will actually benefit more than corporations.

◈ Tone Comparison

Left-leaning outlets and Democrats use words like 'fraud,' 'sham,' and 'sweetheart deal' to describe the J&J and broader MFN arrangements, deploying accusatory language about corporate capture. Right-leaning commentary employs superlatives like 'greatest victory' and 'historic achievement,' framing the deals as triumphs of administration negotiating prowess and free-market persuasion. Democrats emphasize opacity and corporate windfalls; Republicans emphasize tangible discounts and investment commitments.